Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company. It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products. The company was founded on October 1, 2013 and is... 
Surperformance© rating of Actavis Inc
Trading Rating : Investor Rating :
More about the company
Financials ($)
Sales 2014 10 421 M
EBIT 2014 3 039 M
Net income 2014 2 068 M
Debt 2014 6 719 M
Yield 2014 -
Sales 2015 10 690 M
EBIT 2015 3 271 M
Net income 2015 2 808 M
Debt 2015 4 261 M
Yield 2015 -
PER 2014 18,24
PER 2015 15,23
EV / Sales 2014 3,89x
EV / Sales 2015 3,56x
Capitalization 33 841 M
More Financials
Latest news on ACTAVIS INC
3d ago Investors support deals spree, happy to see U.S. companies buy growth
04/02 ACTAVIS : Launches Asia Pacific Regional Headquarters in Singapore
04/01 ACTAVIS : Particle Sciences and Actavis Enter into Joint Development Agreement
04/01 ACTAVIS : Acquires Silom Medical Company
04/01 ACTAVIS : Completes Divestiture of Commercial Operations in Seven Western Europe..
03/28 ACTAVIS : Confirms Favorable Ruling in Generic Lialda® Patent Suit
03/27 A string of mega deals drives global M&A recovery in first-quarter
03/21 ACTAVIS : to Host First Quarter 2014 Earnings Conference Call and Webcast
03/21 ACTAVIS : Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVA..
03/19 ACTAVIS : Announces Daytrana® Patent Challenge Settlement
03/18 Insight - Unease grows among U.S. doctors over Indian drug quality
03/13DJMylan Plans to Start Selling Generic Celebrex in May
More news
Comments 
Advertisement
Income Statement Evolution
Actavis Inc : Income Statement Evolution
More Financials
EPS Revisions
Actavis Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF